Warning! GuruFocus detected
1 Medium warning sign
with 4015.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Jamjoom Pharmaceuticals Factory Co
ISIN : SA15QGU1UNH6
Compare
Compare
Traded in other countries / regions
4015.Saudi IPO Date
2023-06-20Description
Jamjoom Pharmaceuticals Factory Co is engaged in the development, manufacture, and marketing of a wide range of high-quality branded generic pharmaceuticals, including pharmaceuticals and consumer health products, with the majority of revenue coming from pharmaceutical sales. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 125.21 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 3972.39 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 25.19 | |||||
| Beneish M-Score | -1.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.5 | |||||
| 3-Year EBITDA Growth Rate | 25.5 | |||||
| 3-Year EPS without NRI Growth Rate | 29.3 | |||||
| 3-Year FCF Growth Rate | 24.8 | |||||
| 3-Year Book Growth Rate | 6.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 11.69 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.11 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.77 | |||||
| 9-Day RSI | 39.98 | |||||
| 14-Day RSI | 40.65 | |||||
| 3-1 Month Momentum % | -3.42 | |||||
| 6-1 Month Momentum % | -11.52 | |||||
| 12-1 Month Momentum % | 19.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | |||||
| Quick Ratio | 3.76 | |||||
| Cash Ratio | 1.3 | |||||
| Days Inventory | 176.03 | |||||
| Days Sales Outstanding | 146.58 | |||||
| Days Payable | 126.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.1 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| Forward Dividend Yield % | 2.1 | |||||
| 5-Year Yield-on-Cost % | 2.03 | |||||
| Shareholder Yield % | 2.03 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.23 | |||||
| Operating Margin % | 30.73 | |||||
| Net Margin % | 27.04 | |||||
| FCF Margin % | 15.65 | |||||
| ROE % | 24.54 | |||||
| ROA % | 20.12 | |||||
| ROIC % | 27.73 | |||||
| 3-Year ROIIC % | 93.1 | |||||
| ROC (Joel Greenblatt) % | 30.47 | |||||
| ROCE % | 25.04 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.28 | |||||
| Forward PE Ratio | 24.39 | |||||
| PE Ratio without NRI | 27.66 | |||||
| PS Ratio | 7.91 | |||||
| PB Ratio | 6.99 | |||||
| Price-to-Tangible-Book | 7.05 | |||||
| Price-to-Free-Cash-Flow | 50.49 | |||||
| Price-to-Operating-Cash-Flow | 39.58 | |||||
| EV-to-EBIT | 26.57 | |||||
| EV-to-EBITDA | 24.21 | |||||
| EV-to-Revenue | 7.72 | |||||
| EV-to-Forward-Revenue | 6.77 | |||||
| EV-to-FCF | 49.77 | |||||
| Price-to-Graham-Number | 2.94 | |||||
| Price-to-Net-Current-Asset-Value | 13.95 | |||||
| Earnings Yield (Greenblatt) % | 3.76 | |||||
| FCF Yield % | 1.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jamjoom Pharmaceuticals Factory Co Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ï·¼) | 1,318.477 | ||
| EPS (TTM) (ï·¼) | 5.09 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 28.97 | ||
| 14-Day RSI | 40.65 | ||
| 14-Day ATR (ï·¼) | 5.191472 | ||
| 20-Day SMA (ï·¼) | 154.31 | ||
| 12-1 Month Momentum % | 19.85 | ||
| 52-Week Range (ï·¼) | 124.8 - 202.4 | ||
| Shares Outstanding (Mil) | 70 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jamjoom Pharmaceuticals Factory Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jamjoom Pharmaceuticals Factory Co Stock Events
| Event | Date | Price (ï·¼) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jamjoom Pharmaceuticals Factory Co Frequently Asked Questions
What is Jamjoom Pharmaceuticals Factory Co(SAU:4015)'s stock price today?
The current price of SAU:4015 is ï·¼149.00. The 52 week high of SAU:4015 is ï·¼202.40 and 52 week low is ï·¼124.80.
When is next earnings date of Jamjoom Pharmaceuticals Factory Co(SAU:4015)?
The next earnings date of Jamjoom Pharmaceuticals Factory Co(SAU:4015) is .
Does Jamjoom Pharmaceuticals Factory Co(SAU:4015) pay dividends? If so, how much?
The Dividend Yield %  of Jamjoom Pharmaceuticals Factory Co(SAU:4015) is 2.1% (As of Today), Highest Dividend Payout Ratio of Jamjoom Pharmaceuticals Factory Co(SAU:4015) was 0.58. The lowest was 0.24. And the median was 0.41. The  Forward Dividend Yield % of Jamjoom Pharmaceuticals Factory Co(SAU:4015) is 2.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers